Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Proteomics Clin Appl. 2015 Nov 18;10(2):136–143. doi: 10.1002/prca.201400203

Figure 3. Validation of MMP9 in MDM supernatants and plasma of patients with HAND.

Figure 3

Concentration of MMP9 was determined by sandwich ELISA (R&D, Minneapolis, MN). (A) PBMCs were isolated from HIV+ Hispanic women characterized for cognitive function. Supernatant were collected after 6 days of macrophage differentiation. Macrophage supernatants were from HIV− donors (n=5) and HIV+ patients characterized for neurocognitive status of normal cognition (NC, n=6), asymptomatic neurocognitive impairment (ANI, n=9), and HIV-associated dementia (HAD, n=7) were analyzed for MMP9 expression. Macrophages supernatant from ANI had lower levels of MMP9. (B) Plasma from HIV− donors (n=10) and HIV+ patients characterized for neurocognitive status of NC (n=18), ANI (n=19), and HAD (n=23) were analyzed for MMP9 expression. Data were analyzed by one-way ANOVA and Tukey post-test. HIV+ patients, regardless of cognitive status, had lower levels of MMP9 when compared to HIV− donors. *p<0.05; *** p<0.001.